Taking everything into account, studies are in agreement with the fact that anti-tumor compounds are able to inhibit STAT3 in different stages, including targeting upstream mediators, the activation of endogenous inhibitors, the downregulation of downstream targets and suppressing STAT3 expression [167,168,169,170,171,172,173,174]. Here, STAT3 is linked to neoplasm.